A function-blocking PAR4 antibody is markedly antithrombotic in the face of a hyperreactive PAR4 variant

Shauna L. French, Claudia Thalmann, Paul F. Bray, Lynn E. Macdonald, Andrew J. Murphy, Mark W. Sleeman, Justin R. Hamilton

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Thrombin activates human platelets via 2 protease-activated receptors (PARs), PAR1 and PAR4, both of which are antithrombotic drug targets: a PAR1 inhibitor is approved for clinical use, and a PAR4 inhibitor is in trial. However, a common sequence variant in human PAR4 (rs773902, encoding Thr120 in place of Ala120) renders the receptor more sensitive to agonists and less sensitive to antagonists. Here, we develop the first human monoclonal function-blocking antibody to human PAR4 and show it provides equivalent efficacy against the Ala120 and Thr120 PAR4 variants. This candidate was generated from a panel of anti-PAR4 antibodies, was found to bind PAR4 with affinity (KD ≈ 0.4 nM) and selectivity (no detectable binding to any of PAR1, PAR2, or PAR3), and is capable of near-complete inhibition of thrombin cleavage of either the Ala120 or Thr120 PAR4 variant. Platelets from individuals expressing the Thr120 PAR4 variant exhibit increased thrombin-induced aggregation and phosphatidylserine exposure vs those with the Ala120 PAR4 variant, yet the PAR4 antibody inhibited these responses equivalently (50% inhibitory concentration, 4.3 vs 3.2 µg/mL against Ala120 and Thr120, respectively). Further, the antibody significantly impairs platelet procoagulant activity in an ex vivo thrombosis assay, with equivalent inhibition of fibrin formation and overall thrombus size in blood from individuals expressing the Ala120 or Thr120 PAR4 variant. These findings reveal antibody-mediated inhibition of PAR4 cleavage and activation provides robust antithrombotic activity independent of the rs773902 PAR4 sequence variant and provides rationale for such an approach for antithrombotic therapy targeting this receptor.

Original languageEnglish
Pages (from-to)1283-1293
Number of pages11
JournalBlood Advances
Volume2
Issue number11
DOIs
Publication statusPublished - 12 Jun 2018

Cite this

French, Shauna L. ; Thalmann, Claudia ; Bray, Paul F. ; Macdonald, Lynn E. ; Murphy, Andrew J. ; Sleeman, Mark W. ; Hamilton, Justin R. / A function-blocking PAR4 antibody is markedly antithrombotic in the face of a hyperreactive PAR4 variant. In: Blood Advances. 2018 ; Vol. 2, No. 11. pp. 1283-1293.
@article{8c72dbdb54e744689cc2665c49314115,
title = "A function-blocking PAR4 antibody is markedly antithrombotic in the face of a hyperreactive PAR4 variant",
abstract = "Thrombin activates human platelets via 2 protease-activated receptors (PARs), PAR1 and PAR4, both of which are antithrombotic drug targets: a PAR1 inhibitor is approved for clinical use, and a PAR4 inhibitor is in trial. However, a common sequence variant in human PAR4 (rs773902, encoding Thr120 in place of Ala120) renders the receptor more sensitive to agonists and less sensitive to antagonists. Here, we develop the first human monoclonal function-blocking antibody to human PAR4 and show it provides equivalent efficacy against the Ala120 and Thr120 PAR4 variants. This candidate was generated from a panel of anti-PAR4 antibodies, was found to bind PAR4 with affinity (KD ≈ 0.4 nM) and selectivity (no detectable binding to any of PAR1, PAR2, or PAR3), and is capable of near-complete inhibition of thrombin cleavage of either the Ala120 or Thr120 PAR4 variant. Platelets from individuals expressing the Thr120 PAR4 variant exhibit increased thrombin-induced aggregation and phosphatidylserine exposure vs those with the Ala120 PAR4 variant, yet the PAR4 antibody inhibited these responses equivalently (50{\%} inhibitory concentration, 4.3 vs 3.2 µg/mL against Ala120 and Thr120, respectively). Further, the antibody significantly impairs platelet procoagulant activity in an ex vivo thrombosis assay, with equivalent inhibition of fibrin formation and overall thrombus size in blood from individuals expressing the Ala120 or Thr120 PAR4 variant. These findings reveal antibody-mediated inhibition of PAR4 cleavage and activation provides robust antithrombotic activity independent of the rs773902 PAR4 sequence variant and provides rationale for such an approach for antithrombotic therapy targeting this receptor.",
author = "French, {Shauna L.} and Claudia Thalmann and Bray, {Paul F.} and Macdonald, {Lynn E.} and Murphy, {Andrew J.} and Sleeman, {Mark W.} and Hamilton, {Justin R.}",
year = "2018",
month = "6",
day = "12",
doi = "10.1182/bloodadvances.2017015552",
language = "English",
volume = "2",
pages = "1283--1293",
journal = "Blood Advances",
issn = "2473-9529",
publisher = "American Society of Hematology",
number = "11",

}

A function-blocking PAR4 antibody is markedly antithrombotic in the face of a hyperreactive PAR4 variant. / French, Shauna L.; Thalmann, Claudia; Bray, Paul F.; Macdonald, Lynn E.; Murphy, Andrew J.; Sleeman, Mark W.; Hamilton, Justin R.

In: Blood Advances, Vol. 2, No. 11, 12.06.2018, p. 1283-1293.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - A function-blocking PAR4 antibody is markedly antithrombotic in the face of a hyperreactive PAR4 variant

AU - French, Shauna L.

AU - Thalmann, Claudia

AU - Bray, Paul F.

AU - Macdonald, Lynn E.

AU - Murphy, Andrew J.

AU - Sleeman, Mark W.

AU - Hamilton, Justin R.

PY - 2018/6/12

Y1 - 2018/6/12

N2 - Thrombin activates human platelets via 2 protease-activated receptors (PARs), PAR1 and PAR4, both of which are antithrombotic drug targets: a PAR1 inhibitor is approved for clinical use, and a PAR4 inhibitor is in trial. However, a common sequence variant in human PAR4 (rs773902, encoding Thr120 in place of Ala120) renders the receptor more sensitive to agonists and less sensitive to antagonists. Here, we develop the first human monoclonal function-blocking antibody to human PAR4 and show it provides equivalent efficacy against the Ala120 and Thr120 PAR4 variants. This candidate was generated from a panel of anti-PAR4 antibodies, was found to bind PAR4 with affinity (KD ≈ 0.4 nM) and selectivity (no detectable binding to any of PAR1, PAR2, or PAR3), and is capable of near-complete inhibition of thrombin cleavage of either the Ala120 or Thr120 PAR4 variant. Platelets from individuals expressing the Thr120 PAR4 variant exhibit increased thrombin-induced aggregation and phosphatidylserine exposure vs those with the Ala120 PAR4 variant, yet the PAR4 antibody inhibited these responses equivalently (50% inhibitory concentration, 4.3 vs 3.2 µg/mL against Ala120 and Thr120, respectively). Further, the antibody significantly impairs platelet procoagulant activity in an ex vivo thrombosis assay, with equivalent inhibition of fibrin formation and overall thrombus size in blood from individuals expressing the Ala120 or Thr120 PAR4 variant. These findings reveal antibody-mediated inhibition of PAR4 cleavage and activation provides robust antithrombotic activity independent of the rs773902 PAR4 sequence variant and provides rationale for such an approach for antithrombotic therapy targeting this receptor.

AB - Thrombin activates human platelets via 2 protease-activated receptors (PARs), PAR1 and PAR4, both of which are antithrombotic drug targets: a PAR1 inhibitor is approved for clinical use, and a PAR4 inhibitor is in trial. However, a common sequence variant in human PAR4 (rs773902, encoding Thr120 in place of Ala120) renders the receptor more sensitive to agonists and less sensitive to antagonists. Here, we develop the first human monoclonal function-blocking antibody to human PAR4 and show it provides equivalent efficacy against the Ala120 and Thr120 PAR4 variants. This candidate was generated from a panel of anti-PAR4 antibodies, was found to bind PAR4 with affinity (KD ≈ 0.4 nM) and selectivity (no detectable binding to any of PAR1, PAR2, or PAR3), and is capable of near-complete inhibition of thrombin cleavage of either the Ala120 or Thr120 PAR4 variant. Platelets from individuals expressing the Thr120 PAR4 variant exhibit increased thrombin-induced aggregation and phosphatidylserine exposure vs those with the Ala120 PAR4 variant, yet the PAR4 antibody inhibited these responses equivalently (50% inhibitory concentration, 4.3 vs 3.2 µg/mL against Ala120 and Thr120, respectively). Further, the antibody significantly impairs platelet procoagulant activity in an ex vivo thrombosis assay, with equivalent inhibition of fibrin formation and overall thrombus size in blood from individuals expressing the Ala120 or Thr120 PAR4 variant. These findings reveal antibody-mediated inhibition of PAR4 cleavage and activation provides robust antithrombotic activity independent of the rs773902 PAR4 sequence variant and provides rationale for such an approach for antithrombotic therapy targeting this receptor.

UR - http://www.scopus.com/inward/record.url?scp=85060321503&partnerID=8YFLogxK

U2 - 10.1182/bloodadvances.2017015552

DO - 10.1182/bloodadvances.2017015552

M3 - Article

VL - 2

SP - 1283

EP - 1293

JO - Blood Advances

JF - Blood Advances

SN - 2473-9529

IS - 11

ER -